Medication Assisted Treatment. Nicole Gastala, MD

Similar documents
Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Buprenorphine as a Treatment Option for Opioid Use Disorder

Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Opioids Research to Practice

STARTING SUBOXONE IN PRIMARY CARE

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Building capacity for a CHC response to Ontario's Opioid Crisis

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations

Opioid dependence and buprenorphine treatment

Buprenorphine and MAT 101

Opioids Research to Practice

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

Opioids Research to Practice

It s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs

National Opioid Treatment Guideline Dr. Ronald Lim

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

THE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

Buprenorphine pharmacology

Treating Opioid Use Disorders: An Update for Counselors and Other Providers

GOALS AND OBJECTIVES

Fighting Today s Opioid Epidemic

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

Management of Opioid Use Disorder in Primary Care

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

Opioid Dependence and Buprenorphine Management

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Buprenorphine Access in California

2/21/2018. What are Opioids?

Quick Guide. For Physicians. Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Optimizing Suboxone in Opioid Addicts

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Opioids Research to Practice

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

Appendix F Federation of State Medical Boards

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE

Treatment Alternatives for Substance Use Disorders

Opiate Use Disorder and Opiate Overdose

Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement

Medication-Assisted Treatment (MAT) Overview

Management Options for Opioid Dependence:

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

Opioids Research to Practice

MEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID Punta Cana 2018

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

Opioid dependence: Detoxification

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone

Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management. Melissa Weimer, DO, MCR Oregon Health & Science University

CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control

9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN

Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine

Confronting the Opioid Epidemic: Suboxone in Primary Care

Opioid Review and MAT Clinic CDC Guidelines

Medication Assisted Treatment:

Aetna s Initiative on the Opioid Epidemic

Opioid Use in Youth. Amy Yule M.D. March 2,

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

MAT 101: TREATMENT OF OPIOID USE DISORDER

Talking with your doctor

The CARA & Buprenorphine Prescribing for APNs & PAs

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Medication Assisted Treatment

MAT in the Corrections Setting

Understanding and Combating the Heroin Epidemic

Medication Assisted Treatment: Setting Up, Operating, Integrating into Primary Care. Ako Jacintho, MD Director of Addiction Medicine HealthRIGHT 360

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Revised 9/30/2016. Primary Care Provider Pain Management Toolkit

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

HARM REDUCTION & TREATMENT. Devin Reaves MSW

Opioid Use Disorders &Medication Treatment

Opioid Management of Chronic (Non- Cancer) Pain

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

Naltrexone protocol alcohol

THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP

Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018

Corporate Medical Policy

Module 6: Overview Opioid Dependence Treatment with Buprenorphine/Naloxone

Transcription:

Medication Assisted Treatment Nicole Gastala, MD

Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants in the benefits of opioid dependence maintenance therapy. Training Objectives: At the conclusion of the training, the participants will have a better working knowledge of the use of medication in assisting with withdrawal while the patient is undergoing counseling with the goal of tapering and abstinence.

Estimated affects 11.2% of adult US population 3-4% of adult US population on long term opioid Lack of evidence for greater than 12 weeks of treatment 1999-2014 more than 165,000 people died of overdose related to opioid pain medications in US In 2013, 1.9 million persons abused or were dependent on prescription opioid pain medication In primary care, opioid dependence ranged from 3-26% One person dies every 19 minutes from prescription drug use. (Straussner, 2014) Chronic Pain and the Public Health Crisis

58 y/o M with PMHx of COPD on home O2, morbid obesity, OA who transfers care currently on hydrocodone-acetaminophen 7.5 mg-325 mg max 6 per day 47 y/o M with morbid obesity, DM2, Depression, Anxiety, Ankylosing spondylitis currently on hydrocodoneacetaminophen 7.5 mg 325 mg q6 hrs prn 46 y/o F with hx of gastric bypass, anxiety, previously a CNA, newly diagnosed hx of opioid abuse. Husband has ankylosing spondylitis Case Studies

What is your next step?

Opioid Pharmacology Buprenorphine/naloxone (Suboxone)

How Does Buprenorphine Work? High Affinity for Mu Opioid Receptor Competes with other opioids and blocks their effects Displaces heroin or other opiates from receptors (This can produce withdrawal if patient has opiates in system) Slow Dissociation from Mu Opioid Receptor Prolonged therapeutic effect > 24 hours Ceiling Effect on Opiate Effects Poor drug for intoxication purposes Safer in an overdose Formulated with Naloxone Naloxone is poorly absorbed if taken orally Naloxone blocks opiate effects if injected

Mean % Negative Buprenorphine, Methadone, LAAM: Urine Testing for Opioids 100 80 All Subjects LAAM 60 49% 40% Buprenorphine Hi Methadone 40 39% 20 19% Lo Methadone 0 1 3 5 7 9 11 13 15 17 Study Week Adapted from Johnson, et al., 2000

Clinical Uses of Buprenorphine Withdrawal & Detoxification Maintenance Prevents withdrawal Diminishes craving Does not produce a high Blocks (or reduces effect of) heroin Increases treatment retention

Starting a MAT program in Primary Care

Figure 1. US counties with physicians with waivers to prescribe buprenorphine. At least 1 buprenorphine provider No buprenorphine providers Note: data source: Drug Enforcement Administration, July 2012. Map date: September 2013. ANNALS OF FAMILY MEDICINE WWW.ANNFAMMED.ORG VOL. 13, NO. 1 JANUARY/FEBRUARY 2015

Set your protocols (induction, maintenance, tapering, and discharge) Create a patient/clinic agreement Referral Process (accepting patients and coordinating with psychosocial services) Drug testing (company and frequency, observed or unobserved) Find a mentor and/or consider joining an ECHO Focus on team-based care and whole patient treatment Starting a MAT program in primary care

Pain team: BHC, RN, LPN, MD, PA, ARNP, Nurse Care Mgr Weekly review of MAT patients Review of drug screens and counseling reports Time to discuss challenging cases Plan of care for the following week Team-Based Care: Weekly Staffing

Drug Testing

Take Home Points for MAT Helps with withdrawal while patient is undergoing counseling and substance treatment Buprenorphine/Naloxone is safe and effective in suppressing withdrawal symptoms and blocking the effects of illicit opioids Safe Medication Overdose with Buprenorphine/Naloxone has a low likelihood of clinically significant problems. Morbidity and mortality are linked to use with other drugs such as benzodiazepines.

Take Home Points for MAT Patients can continue to function on medication leading to stabilization in home/work environment Does not cause disruption in cognitive and psychomotor performance or end-stage organ damage Diversion potential exists but is less than prescribed opioids or methadone Can be done in the primary care office setting after receiving appropriate training You have the ability to change patient outcomes in your community!

NGastala@phcinc.net Primary Health Care, Inc - Marshalltown Thank you!